Alliancebernstein L.P. Exelixis, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Exelixis, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 405,020 shares of EXEL stock, worth $13.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,020

Previous 462,968 12.52%

Holding current value

$13.4 Million

Previous $10.4 Million 1.04%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $1.27 Million - $1.6 Million	-57,948 Reduced 12.52%	405,020 $10.5 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $1.51 Million - $1.77 Million	-74,418 Reduced 13.85%	462,968 $10.4 Million
Q1 2024 May 14, 2024	SELL	$20.17 - $23.93 $925,782 - $1.1 Million	-45,899 Reduced 7.87%	537,386 $12.8 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $1.01 Million - $1.26 Million	52,328 Added 9.86%	583,285 $14 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $93,143 - $111,244	-4,892 Reduced 0.91%	530,957 $11.6 Million
Q2 2023 Aug 15, 2023	BUY	$18.17 - $20.48 $282,470 - $318,382	15,546 Added 2.99%	535,849 $10.2 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $2.71 Million - $3.23 Million	-166,559 Reduced 24.25%	520,303 $10.1 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $46,555 - $54,117	3,112 Added 0.46%	686,862 $11 Million
Q3 2022 Nov 15, 2022	BUY	$15.68 - $22.27 $66,875 - $94,981	4,265 Added 0.63%	683,750 $10.7 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $1.98 Million - $2.63 Million	-113,631 Reduced 14.33%	679,485 $14.1 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $5.25 Million - $6.99 Million	308,309 Added 63.59%	793,116 $18 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $1.32 Million - $1.82 Million	-83,400 Reduced 14.68%	484,807 $8.86 Million
Q3 2021 Nov 10, 2021	BUY	$16.3 - $21.14 $1.1 Million - $1.42 Million	67,298 Added 13.44%	568,207 $12 Million
Q2 2021 Jul 30, 2021	SELL	$17.95 - $25.56 $4.25 Million - $6.06 Million	-236,903 Reduced 32.11%	500,909 $9.13 Million
Q1 2021 May 06, 2021	BUY	$20.53 - $25.22 $1.77 Million - $2.18 Million	86,400 Added 13.26%	737,812 $16.7 Million
Q4 2020 Feb 08, 2021	SELL	$18.39 - $24.8 $1.07 Million - $1.45 Million	-58,400 Reduced 8.23%	651,412 $13.1 Million
Q3 2020 Nov 12, 2020	BUY	$20.67 - $26.94 $842,653 - $1.1 Million	40,767 Added 6.09%	709,812 $17.4 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $533,468 - $888,682	32,410 Added 5.09%	669,045 $15.9 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $1.76 Million - $2.65 Million	121,652 Added 23.62%	636,635 $11 Million
Q4 2019 Feb 18, 2020	BUY	$15.15 - $18.89 $12,120 - $15,112	800 Added 0.16%	514,983 $9.07 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $62,056 - $79,501	-3,510 Reduced 0.68%	514,183 $9.09 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $118,747 - $155,256	6,273 Added 1.23%	517,693 $11.1 Million
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $1.83 Million - $2.31 Million	-93,380 Reduced 15.44%	511,420 $12.2 Million
Q4 2018 Feb 13, 2019	SELL	$13.65 - $21.8 $2.95 Million - $4.72 Million	-216,380 Reduced 26.35%	604,800 $11.9 Million
Q3 2018 Nov 08, 2018	BUY	$15.87 - $22.4 $6.31 Million - $8.91 Million	397,695 Added 93.91%	821,180 $14.6 Million
Q2 2018 Aug 13, 2018	BUY	$18.56 - $22.45 $4.94 Million - $5.97 Million	265,905 Added 168.74%	423,485 $9.11 Million
Q1 2018 May 14, 2018	SELL	$22.15 - $31.89 $314,530 - $452,838	-14,200 Reduced 8.27%	157,580 $3.49 Million
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $23,018 - $29,383	-950 Reduced 0.55%	171,780 $5.22 Million
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $4.03 Million - $5.05 Million	172,730	172,730 $4.19 Million

Others Institutions Holding EXEL

# of Institutions

520

Shares Held

244M

Call Options Held

2.84M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Exelixis, Inc. Transaction History